By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Salix Pharmaceuticals, Inc. et al. v. Novel Laboratories, Inc.
3:08-cv-02311; filed May 14, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 7,169,381 ("Colon Cleansing Compositions and Methods," issued January 30, 2007) following a paragraph IV certification as part of Novel's filing of an ANDA to manufacture a generic version of Salix's MoviPrep® (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid oral solution, used for cleansing of the colon as a preparation for colonoscopy). View the complaint here.
Bayer Schering Pharma AG et al. v. Sandoz, Inc.
1:08-cv-00980; filed May 12, 2008 in the District Court of Colorado
Infringement of U.S. Patent No. 5,569,652 ("Dihydrospirorenone as an Antiandrogen," issued October 29, 1996) following a paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Bayer's Yasmin® (drospirenone and ethinyl estradiol, used as oral contraception). View the complaint here.
Novartis Pharmaceuticals Corporation et al. v. Roxane Laboratories, Inc.
2:08-cv-02272; filed May 9, 2008 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,840,763 ("Treatment of a Latent Infection of Herpes Viruses, issued November 24, 1998), 5,916,893 (same title, issued June 29, 1999), and 5,866,581 ("Penciclovir for the Treatment of Post Therapeutic Neuralgia," issued February 2, 1999) following a paragraph IV certification as part of Roxane's filing of an ANDA to manufacture a generic version of Novartis' Famvir® (famciclovir, used for the treatment of acute herpes zoster (shingles), the treatment or suppression of recurrent genital herpes in immunocompentent patients, the treatment of recurrent herpes labialis (cold sores) in immunocompetent patients, and the treatment of recurrent mucotaneous herpes simplex infections in HIV-infected patients). View the complaint here.
Pamlab, L.L.C. et al. v. Hi-Tech Pharmacal Co., Inc. et al.
1:08-cv-00967; filed May 8, 2008 in the District Court of Colorado
Infringement of U.S. Patent No. 6,528,496 ("Compositions Treating, Preventing, or Reducing Elevated Metabolic Levels," issued March 4, 2003) based on defendants' manufacture and sale of its Folamin, allegedly the same as Pamlab's Foltx® (vitamin B12, vitamin B6, and folic acid, used to treat hyperhomocysteinemia). View the complaint here.
Comments